Clinical Trial: Combinations of Pharmacologic Smoking Cessation Treatments


	Home	\|	Search	\|	Browse	\|	Resources	\|	Help	\|	What's New	\|	About

Combinations of Pharmacologic Smoking Cessation Treatments

This study is currently recruiting patients.

Sponsored by:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs

Purpose

The purpose of this study is to test the effectiveness of a combination of the drugs bupropion and mecamylamine along with a nicotine patch as a therapy for smoking cessation.

Condition	Treatment or Intervention	Phase
Smoking	Drug: Bupropion Drug: Mecamylamine Drug: Nicotine Patch	Phase I

MedlinePlus related topics: Smoking

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study

Further Study Details:

Study start: November 1998; Study completion: June 2001

Eligibility

Ages Eligible for Study: 20 Years - 40 Years, Genders Eligible for Study: Both

Criteria

Subjects must be a smoker between 20 and 40 years old, have smoked at least 20 cigarettes per day for at least 2 years, wish to stop smoking and be in good general health

Location and Contact Information

California
VA Greater Los Angeles Healthcare System, Los Angeles, California, 90073, United States; Recruiting

Richard E. Olmstead, Ph.D. 310-478-3711 Ext. 44300 olmstead@nicco.sscnet.ulca.edu
Richard E. Olmsted, Principal Investigator

Study chairs or principal investigators

Neil Hartman, M.D.

More Information

Study ID Numbers: ADRD-011-98S
Record last reviewed: June 2001
Record first received: July 3, 2001
ClinicalTrials.gov Identifier: NCT00018187
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-09

U.S. National Library of Medicine, Contact NLM Customer Service

National Institutes of Health, Department of Health & Human Services